The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and prognostic stratification. A systematic literature search up to May 2024 was conducted in the PubMed, Embase and Scopus databases. Articles with mixed risk patient populations, review articles, editorials, letters, comments, or case reports were excluded. The quality of the papers was assessed by using the CASP criteria. The literature search returned 1111 studies; however, 1105 articles were excluded, and therefore 6 full-text papers were retrieved for the final analysis. Three out of six papers focused on the utility of SUVmax in identifying high ISUP grade in patients with intermediate-risk PCa. The latest three papers discussed the controversial role of PSMA PET/CT in predicting the lymph node involvement, mainly in the case of favorable subset. PSMA PET has completely changed the management of patients with PCa; indeed its role is still undefined in patients with intermediate-risk disease. Future perspective is to investigate larger cohorts of intermediate-risk PCa patients, to fully recognize the added value offered by PSMA PET in this category of subjects.
Annals of nuclear medicine. 2025 Jan 15 [Epub ahead of print]
Priscilla Guglielmo, Nicolò Buffi, Angelo Porreca, Lucia Setti, Demetrio Aricò, Lorenzo Muraglia, Laura Evangelista
Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy. ., Department of Biomedical Sciences, Humanitas University, Milan, Italy., Department of Oncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy., Department of Nuclear Medicine, Humanitas Oncological Centre of Catania, 95125, Catania, Italy., Nuclear Medicine Unit, Humanitas Clinical and Research Institute IRCCS, Rozzano, Italy.